Skin-cleansing soaps, foams, lotion recalled over possible "serious and life-threatening infections"

Skin-cleansing soaps, foams, lotion recalled over possible “serious and life-threatening infections”

A U.S. company that makes health care products is recalling four over-the-counter skin cleansers and an anti-itch lotion it says could lead to “serious and life-threatening infections.”  New Jersey-based DermaRite Industries announced on Friday that it was voluntarily recalling the health care products due to the fact that they may cause a microbial contamination known as…

Read More
Influencers promote raw milk despite FDA health warnings as bird flu spreads in dairy cows

Influencers promote raw milk despite FDA health warnings as bird flu spreads in dairy cows

On May 7, health influencer Paul Saladino, M.D.. posted a video to his X account that promoted feeding “raw dairy” to infants. The post received over 90,000 views and sparked strong backlash before it was removed the following day. Saladino regularly advocates for “animal-based” diets featuring raw milk, including on his TikTok channel where he…

Read More
Power Stick deodorant recalled from retailers because of manufacturing defects

Power Stick deodorant recalled from retailers because of manufacturing defects

Some Power Stick deodorants manufactured by A.P. Deauville are under recall for manufacturing defects, according to the Food and Drug Administration. The recall impacts more than 67,000 cases of roll-on deodorants that were sold nationally, a notice posted by the agency shows. The issue is related to deviations with “current good manufacturing practices,” a set…

Read More
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection

The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative. Daniel O’Day, Gilead’s chairman and chief executive officer, called…

Read More